SCHEMBL12407751

SCHEMBL12407751

Cc1ccc(S(=O)(=O)N(CC(=O)NCc2cccc(C(=O)O)c2)c2cccc(C)c2)cc1

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ RORC P51449 4/20 0.62
▸ ALDH1A1 P00352 2/20 0.62
▸ SMN1; SMN2 Q16637 2/20 0.62
▸ LMNA P02545 2/20 0.62
▸ HPGD P15428 1/20 0.62
▸ HTT P42858 1/20 0.62
▸ PTGER1 P34995 7/20 0.58
▸ THRB P10828 1/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ POLB P06746 1/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ CYP2D6 P10635 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ MAPT P10636 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12407773 0.96 RORC (0.64) RORCALDH1A1SMN1; SMN2LMNAHPGD
SCHEMBL12407696 0.94 LMNA (0.64) RORCALDH1A1SMN1; SMN2LMNAHPGD
SCHEMBL12407775 0.92 RORC (0.60) RORCALDH1A1SMN1; SMN2LMNAHPGD
SCHEMBL12407792 0.92 RORC (0.60) RORCALDH1A1SMN1; SMN2LMNAHPGD
SCHEMBL12407759 0.92 RORC (0.60) RORCALDH1A1SMN1; SMN2LMNAHPGD
SCHEMBL12407769 0.92 RORC (0.61) RORCALDH1A1SMN1; SMN2LMNAHPGD
SCHEMBL12407777 0.91 RORC (0.59) RORCALDH1A1SMN1; SMN2LMNAHPGD
SCHEMBL12407790 0.91 RORC (0.59) RORCALDH1A1SMN1; SMN2LMNAHPGD
SCHEMBL12407762 0.91 PTGER1 (0.64) RORCALDH1A1SMN1; SMN2LMNAHPGD
SCHEMBL12407757 0.91 RORC (0.62) RORCALDH1A1SMN1; SMN2LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973078-B2 Sulfonamide compound or salt thereof ASTELLAS PHARMA INC. (JP) 2011-07-05 — — US disclosed
US-20090312328-A1 SULFONAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-12-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312328-A1 SULFONAMIDE COMPOUND OR SALT THEREOF PTGER1, CYSLTR1, PTGER2 RORC 2688/4885ALDH1A1 511/4885SMN1; SMN2 731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback